







an Open Access Journal by MDPI

# Diagnostics and Vaccine Development for Emerging Infectious Diseases

Guest Editor:

#### Dr. Syed Faraz Ahmed

Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, Australia

Deadline for manuscript submissions:

closed (10 May 2023)

## **Message from the Guest Editor**

This Special Issue focuses on the design of diagnostics and vaccines for different types of emerging infectious diseases. Examples include HIV infection, filovirus diseases, flavivirus diseases, Nipah virus infection, and the coronaviruses. We need to continually develop better diagnostic tools that can provide early detection of pathogens, agents of infectious diseases. Second, given the diversity of these pathogens and the heterogeneity of ways in which the human immune system may be primed to control and provide protection, there is an urgent need to design and develop multiple different platforms for next-generation vaccines.

It is very important that we identify precise and practical targets for designing effective diagnostics that can be quickly translated into development. In addition, increasing the availability of new vaccine design platforms such as mRNA and viral vector technologies as well as the progress in peptide-based multi-epitope vaccines, including in identifying precise and potent targets for the design of effective vaccines against emerging infectious diseases, is needed now more than ever.

I look forward to receiving your contributions.













an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

## **Message from the Editor-in-Chief**

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

#### **Author Benefits**

**Open Access:** free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### **Contact Us**